Press Release

Technology Industry Veteran Phil Mui Joins HeartFlow Product & Engineering Team

REDWOOD CITY, Calif. – July 21, 2015 – HeartFlow, Inc., a pioneer in personalized medical technology for cardiovascular disease, announced the addition of Phil Mui as senior vice president of engineering and product. A former technology executive of Google and Acxiom, Mui will be responsible for guiding the scalable development of HeartFlow’s technology platform. The company’s HeartFlow® FFRCT Analysis is the first and only non-invasive technology to offer physicians insight on both the extent of a patient’s arterial blockage, as well as any impact on blood flow.

“Phil’s extensive knowledge and experience in engineering, along with his considerable energy, will greatly benefit HeartFlow, particularly as we look to further enhance our products by incorporating additional cutting-edge technology,” said Charles Taylor, founder and chief technology officer of HeartFlow. “The breadth and depth of his understanding of product development and streamlining engineering practices makes him an ideal addition to our team, and we are very lucky to have him.”

Prior to joining HeartFlow, Mui was executive vice president, chief technology and product innovation officer for Acxiom, a marketing technology and services company where he led agile engineering, product and marketing teams to build data science and marketing products. While there, he also created the Acxiom Innovation Lab for long-term research and development with industry partners, including, Microsoft, and others. Prior to joining Acxiom, he spent nearly seven years at Google, where he led the Google Analytics team and other infrastructure projects.

“Phil brings unparalleled knowledge of how to develop truly scalable technology offerings, which will enable us to meet the needs of HeartFlow’s customers in a rapid fashion as our clinical platform is adopted at leading hospitals around the world,” said John Stevens, CEO of HeartFlow. “His skill in designing nimble teams and infrastructure will be critical as we continue to expand our reach over the coming year.”

Mui’s work has received several prestigious industry awards, including the 2013 American Business Award for Favorite Marketing Product, the 2014 People’s Choice Stevie Award for Most Innovative Marketing Product, the MediaPost 2014 Media Supplier of the Year, and the 2014 Walmart Supplier of the Year.

Mui graduated from the Massachusetts Institute of Technology with bachelor’s and master’s degrees in engineering, as well as a doctorate in electrical engineering and computer science. He also holds a master’s degree in management from Oxford, where he was a Marshall Scholar.

About HeartFlow

HeartFlow, Inc. is a personalized medical technology company dedicated to transforming the way cardiovascular disease is managed. Committed to improving outcomes, reducing costs and creating a better patient experience, HeartFlow’s goal is to provide healthcare professionals with actionable knowledge about each patient by combining best-in-class, non-invasive healthcare imaging with advanced, computational fluid dynamics technology and the insights of big data. Its non-invasive HeartFlow FFRCT Analysis helps physicians diagnose coronary artery disease and provides them with information they need to manage each patient. For more information visit

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.